Literature DB >> 4062447

Cost containment of the second-generation cephalosporins by prospective monitoring at a community teaching hospital.

R R Williams, P A Gross, J F Levine.   

Abstract

All patients receiving cefoxitin and cefamandole were prospectively reviewed for appropriate and inappropriate utilization. There were two eight-week survey periods. In period 1, 81 (70%) of 115 patients received cefoxitin appropriately and six (40%) of 15 patients received cefamandole appropriately. In patients receiving antibiotics inappropriately, 12 (35%) of the 34 receiving cefoxitin and eight (89%) of the nine receiving cefamandole had infections that could have been treated with less expensive, equally efficacious antibiotics. Changes in antibiotic therapy were made in 79% of patients based on our recommendations. The estimated annual cost saving for these antibiotics was $40,290. During period 2, 73 (91%) of 80 patients were given cefoxitin appropriately and 14 (61%) of 23 patients received cefamandole appropriately. Forty-three percent of those receiving cefoxitin and 33% of those receiving cefamandole inappropriately could have been treated with a less expensive, equally efficacious antibiotic. In 88% of patients, the attending physicians followed our recommendations.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4062447

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  3 in total

Review 1.  The role of the infectious diseases physician in monitoring antimicrobial use: a pharmacy perspective.

Authors:  R E Polk
Journal:  Bull N Y Acad Med       Date:  1987 Jul-Aug

2.  Containing cefoxitin costs through a program to curtail use in surgical prophylaxis.

Authors:  G Taylor; E Blondel-Hill; P Kibsey; E Friesen; R Tisdell; W Vaudry
Journal:  Can J Infect Dis       Date:  1993-09

Review 3.  Cephalosporin utilisation review and evaluation.

Authors:  G M Misan; C Dollman; D R Shaw; N Burgess
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.